High Tech Pharm Co. Ltd (106190) - Cash Flow Conversion Efficiency
Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.60 Billion ≈ $4.47 Million USD) by net assets (₩126.99 Billion ≈ $86.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See High Tech Pharm Co. Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
High Tech Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
High Tech Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferronordic AB (publ)
ST:FNM
|
-0.108x |
|
AMC Robotics Corporation
NASDAQ:AMCI
|
-0.037x |
|
WMG Holdings Bhd
KLSE:6378
|
0.065x |
|
Bunzl PLC
LSE:BNZL
|
0.144x |
|
Poalim Ibi
TA:PIU
|
0.048x |
|
51 CREDIT CARD DL-00001
F:2JY
|
N/A |
|
LOGISTRI FASTIGHETS AB
F:6DV
|
N/A |
|
Fima Corporation Bhd
KLSE:3107
|
0.110x |
Annual Cash Flow Conversion Efficiency for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of High Tech Pharm Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see High Tech Pharm Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩119.74 Billion ≈ $81.14 Million |
₩14.69 Billion ≈ $9.96 Million |
0.123x | +351.33% |
| 2023-12-31 | ₩106.99 Billion ≈ $72.51 Million |
₩2.91 Billion ≈ $1.97 Million |
0.027x | +173.37% |
| 2022-12-31 | ₩99.94 Billion ≈ $67.73 Million |
₩-3.70 Billion ≈ $-2.51 Million |
-0.037x | -150.21% |
| 2021-12-31 | ₩93.88 Billion ≈ $63.62 Million |
₩6.93 Billion ≈ $4.69 Million |
0.074x | +191.29% |
| 2020-12-31 | ₩95.14 Billion ≈ $64.48 Million |
₩-7.69 Billion ≈ $-5.21 Million |
-0.081x | -420.83% |
| 2019-12-31 | ₩98.58 Billion ≈ $66.81 Million |
₩2.48 Billion ≈ $1.68 Million |
0.025x | -51.59% |
| 2018-12-31 | ₩103.35 Billion ≈ $70.04 Million |
₩5.38 Billion ≈ $3.65 Million |
0.052x | -2.44% |
| 2017-12-31 | ₩102.19 Billion ≈ $69.26 Million |
₩5.45 Billion ≈ $3.69 Million |
0.053x | +272.82% |
| 2016-12-31 | ₩101.18 Billion ≈ $68.57 Million |
₩1.45 Billion ≈ $981.14K |
0.014x | -89.06% |
| 2015-12-31 | ₩97.20 Billion ≈ $65.87 Million |
₩12.71 Billion ≈ $8.61 Million |
0.131x | +18.32% |
| 2014-12-31 | ₩92.06 Billion ≈ $62.39 Million |
₩10.17 Billion ≈ $6.89 Million |
0.110x | -- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.